FIXX Homology Medicines Inc

Price (delayed)

$6.86

Market cap

$391.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$300.73M

Highlights
FIXX's EPS is up by 28% from the previous quarter and by 22% YoY
FIXX's net income is up by 27% since the previous quarter and by 18% year-on-year
FIXX's quick ratio is down by 21% year-on-year but it is up by 11% since the previous quarter
FIXX's equity is down by 11% year-on-year but it is up by 2.5% since the previous quarter

Key stats

What are the main financial stats of FIXX
Market
Shares outstanding
57.08M
Market cap
$391.6M
Enterprise value
$300.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.72
Price to sales (P/S)
11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.57
Earnings
Revenue
$31.42M
EBIT
-$94.44M
EBITDA
-$85.3M
Free cash flow
-$100.83M
Per share
EPS
-$2.03
Free cash flow per share
-$2
Book value per share
$3.98
Revenue per share
$0.62
TBVPS
$4.66
Balance sheet
Total assets
$234.7M
Total liabilities
$33.87M
Debt
$14.82M
Equity
$200.83M
Working capital
$173.84M
Liquidity
Debt to equity
0.07
Current ratio
10.76
Quick ratio
10.67
Net debt/EBITDA
1.07
Margins
EBITDA margin
-271.5%
Gross margin
100%
Net margin
-300.6%
Operating margin
-302%
Efficiency
Return on assets
-38.3%
Return on equity
-49.6%
Return on invested capital
-126.7%
Return on capital employed
-43.5%
Return on sales
-300.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FIXX stock price

How has the Homology Medicines stock price performed over time
Intraday
-5.51%
1 week
-4.32%
1 month
2.54%
1 year
-56.53%
YTD
-39.24%
QTD
-27.1%

Financial performance

How have Homology Medicines's revenue and profit performed over time
Revenue
$31.42M
Gross profit
$31.42M
Operating income
-$94.88M
Net income
-$94.44M
Gross margin
100%
Net margin
-300.6%
FIXX's net margin has surged by 95% year-on-year and by 94% since the previous quarter
The operating margin has soared by 95% YoY and by 94% from the previous quarter
FIXX's net income is up by 27% since the previous quarter and by 18% year-on-year
The operating income is up by 27% since the previous quarter and by 22% year-on-year

Growth

What is Homology Medicines's growth rate over time

Valuation

What is Homology Medicines stock price valuation
P/E
N/A
P/B
1.72
P/S
11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.57
FIXX's EPS is up by 28% from the previous quarter and by 22% YoY
The P/B is 39% below the last 4 quarters average of 2.8
FIXX's equity is down by 11% year-on-year but it is up by 2.5% since the previous quarter
The P/S is 94% less than the last 4 quarters average of 184.2

Efficiency

How efficient is Homology Medicines business performance
Homology Medicines's return on invested capital has shrunk by 124% YoY but it has increased by 22% QoQ
FIXX's ROS has soared by 95% YoY and by 94% from the previous quarter
The return on equity has increased by 24% since the previous quarter but it has declined by 10% year-on-year
The ROA has grown by 23% from the previous quarter but it has contracted by 4.4% YoY

Dividends

What is FIXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FIXX.

Financial health

How did Homology Medicines financials performed over time
The total liabilities has plunged by 50% from the previous quarter and by 46% YoY
FIXX's quick ratio is down by 21% year-on-year but it is up by 11% since the previous quarter
FIXX's debt is 93% smaller than its equity
FIXX's debt is down by 14% year-on-year and by 4% since the previous quarter
Homology Medicines's debt to equity has decreased by 13% from the previous quarter and by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.